Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

$10.2 million in operating activities in the year ended May 31, 2008 compared with $6.3 million during the year ended May 31, 2007 reflecting the increase in research and development activities during the year. At May 31, 2008, Lorus had cash and cash equivalents, short-term investments and marketable securities of $9.4 million compared to $12.2 million at May 31, 2007. Lorus believes that its current cash and cash equivalents, short-term investments and marketable securities and interest income will be sufficient to carry out the current research and development plans and operations through to the first quarter of fiscal 2010.

Lorus Therapeutics Inc.

Consolidated Statements of Loss

Years Ended May 31

-------------------------------------

(Canadian dollars) 2008 2007 2006

-------------------------------------------------------------------------

REVENUE $ 133 $ 107 $ 26

-------------------------------------------------------------------------

EXPENSES

Cost of sales 2 16 3

Research and development 6,087 3,384 10,237

General and administrative 3,888 3,848 4,334

Stock-based compensation 719 503 1,205

Depreciation and amortization of

fixed assets 317 402 771

-------------------------------------------------------------------------

Operating expenses 11,013 8,153 16,550

Interest expense on convertible

debentures 1,029 1,050 882

Accretion in carrying value of

convertible debentures 1,045
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Sequenom, Inc. (NASDAQ: SQNM ), a ... announced the acceptance for publication of the manuscript, "Clinical ... of Developing Choroidal Neovascular Age-related Macular Degeneration." The article ... Genomics . The study, conducted by the company,s wholly-owned ...
... who design new materials often struggle to understand ... including polymers and biological materials change upon cooling ... a tar-like consistency at intermediate temperatures, then become ... lower temperatures. Scientists have long sought a molecular-level ...
... Researchers at Northwestern University have created a new ... invisible in the terahertz range. Though this ... the visible spectrum, it could have implications in ... by Cheng Sun, assistant professor of mechanical engineering ...
Cached Biology Technology:Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 2Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 3Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 4Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 5Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 6Understanding how glasses 'relax' provides some relief for manufacturers 2Researchers create terahertz invisibility cloak 2
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... researchers report that common assumptions employed in the generation ... can lead to seriously flawed conclusions about gene activity ... biological research. "Expression analysis is one of the ... Member Richard Young. "So we are concerned that flawed ...
... new collaborative project among researchers from Uppsala University in ... first time, demonstrated experimentally the evolutionary force behind the ... of seed beetle. This mechanism is revealed ... Current Biology . The experiments leading to this ...
... PITTSBURGHWhile Omega-3 essential fatty acidsfound in foods like wild ... their effects on the working memory of healthy young ... the first study of its kind, researchers at the ... ages 18-25 can improve their working memory even further ...
Cached Biology News:Whitehead scientists identify major flaw in standard approach to global gene expression analysis 2Size does matter in sexual selection, at least among beetles 2Omega-3 intake heightens working memory in healthy young adults 2Omega-3 intake heightens working memory in healthy young adults 3
Adhesion Molecule Antibodies...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Biology Products: